A Study of GW842166 in Adults With Osteoarthritis Pain
Launched by GLAXOSMITHKLINE · Mar 12, 2007
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • male or female outpatient, \>= 40 years of age
- • meets ACR clinical and radiographic criteria for classification of idiopathic (primary) osteoarthritis of the knee with symptom duration for at least 3 months
- • meets ARA functional status requirements
- • meets WOMAC pain subscale score requirements
- • has taken analgesics for the treatment of their knee OA for at least 4 out of 7 days in each of the 4 weeks preceding screen
- Exclusion Criteria:
- • any pre-specified clinical/biological/ECG abnormality
- • any pre-specified drug sensitivity
- • history of peptic ulceration or GI bleeding
- • use of protocol-specified medications
- • secondary cause of knee OA
- • lower extremity surgery within 6 months of screening
- • use of analgesics other than allowed per protocol
- • use of corticosteroids or hyaluronan outside of allowed window prior to screening
About Glaxosmithkline
GlaxoSmithKline (GSK) is a global healthcare company dedicated to improving the quality of human life by enabling people to do more, feel better, and live longer. With a strong focus on research and development, GSK specializes in pharmaceuticals, vaccines, and consumer health products. The company is committed to advancing innovative therapies and preventive measures across various therapeutic areas, including respiratory, oncology, immunology, and infectious diseases. GSK's collaborative approach and rigorous clinical trial processes underscore its dedication to delivering safe and effective healthcare solutions that meet the needs of patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Göteborg, , Sweden
Koeln, Nordrhein Westfalen, Germany
Madrid, , Spain
La Coruña, , Spain
Santiago De Compostela, , Spain
Hamburg, , Germany
Schmiedeberg, Sachsen, Germany
Odense C, , Denmark
Muenchen, Bayern, Germany
Essen, Nordrhein Westfalen, Germany
Helsingborg, , Sweden
Berlin, , Germany
Hvidovre, , Denmark
Leipzg, Sachsen, Germany
Centelles, , Spain
Petrer/Alicante, , Spain
Höllviken, , Sweden
Stocholm, , Sweden
Upplands Väsby, , Sweden
Patients applied
Trial Officials
GSK Clinical Trials, BSc MB PhD
Study Director
GlaxoSmithKline
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials